RNA

Atrium Therapeutics Inc

Feb 25 • 04:00PM ET

7.28

+0.01 0.07 %

Healthcare • Biotechnology • USA • NASD

Peers: MRNA VRTX SRPT ALNY IONS ARWR NBIX BLUE EXEL SGMO

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	-	Perf Week	-0.08%
Market Cap	-	Forward P/E	-	EPS next Y	-	Insider Trans	-2.49%	Shs Float	-	Perf Month	0.22%
Enterprise Value	-	PEG	-	EPS next Q	-	Inst Own	-	Short Float	-	Perf Quarter	2.25%
Income	-	P/S	-	EPS this Y	-	Inst Trans	-11.67%	Short Ratio	4.15	Perf Half Y	54.73%
Sales	-	P/B	-	EPS next Y	-	ROA	-	Short Interest	101.57M	Perf YTD	0.93%
Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W High	7.31 -0.36%	Perf Year	149.66%
Cash/sh	-	P/FCF	-	EPS past 3/5Y	- -	ROIC	-	52W Low	2.15 238.45%	Perf 3Y	219.72%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	0.30% 0.30%	Perf 5Y	186.50%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	0.02	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	-	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	57.58	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	-	EPS Q/Q	-	SMA20	-0.00%	Beta	0.93	Target Price	-
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	0.42%	Rel Volume	0.00	Prev Close	7.28
Employees	-	LT Debt/Eq	-	Earnings	Nov 10 AMC	SMA200	38.79%	Avg Volume	24.50M	Price	7.28
IPO	Jun 12, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-17.02% 545.33%	Trades		Volume	120,556,250	Change	0.07%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-17-25	Initiated	Roth Capital	Buy	$62
Jul-10-25	Resumed	Goldman	Buy	$55
Jun-24-25	Initiated	Bernstein	Outperform	$50
Jun-17-25	Initiated	Wolfe Research	Outperform	$55
Jun-11-25	Initiated	Raymond James	Strong Buy	$65
Mar-13-25	Initiated	Citigroup	Buy	$70
Mar-12-25	Initiated	BMO Capital Markets	Outperform	$72
Mar-07-25	Initiated	Scotiabank	Sector Outperform	$70
Dec-20-24	Initiated	H.C. Wainwright	Buy	$72
Nov-26-24	Initiated	RBC Capital Mkts	Outperform	$67
Sep-24-24	Initiated	Goldman	Buy	$59
Aug-28-24	Initiated	Barclays	Overweight	$63
May-03-24	Initiated	BofA Securities	Buy	$40
Mar-14-24	Initiated	Cantor Fitzgerald	Overweight	$60
May-22-23	Upgrade	Evercore ISI	In-line → Outperform	$20
Mar-31-23	Downgrade	Evercore ISI	Outperform → In-line	$20
Jul-20-22	Initiated	Chardan Capital Markets	Buy	$29
Jul-12-22	Initiated	Raymond James	Strong Buy	$29
Sep-07-21	Initiated	Evercore ISI	Outperform	$50
Jun-17-21	Initiated	Needham	Buy	$50

Show Previous Ratings

Feb-26-26 04:02PM	Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (PR Newswire)
Feb-23-26 08:00AM	Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders (PR Newswire)
Feb-18-26 05:00PM	The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1 (PR Newswire)
Feb-04-26 09:32AM	Novartis Beats on Q4 Earnings, Entresto Generics Pressure Sales (Zacks)
Feb-02-26 09:44PM	Avidity Biosciences Announces Expected Record Date for Spin-Off (PR Newswire)
07:10AM	Loading…
Jan-22-26 07:10AM	Immunocore (IMCR) Soars 5.9%: Is Further Upside Left in the Stock? (Zacks)
Jan-13-26 11:43AM	JPM26: Novartis strengthens neuroscience portfolio with bolt-on deals (Pharmaceutical Technology)
Dec-09-25 08:57AM	Novartis Drops $1.7 Billion on AI Allergy Breakthrough (GuruFocus.com)
Dec-04-25 01:59PM	Avidity Biosciences, Inc. (RNA): A Bull Case Theory (Insider Monkey)
Dec-01-25 06:59PM	Halper Sadeh LLC Encourages RNA, TCBX, ATXS, FSUN Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
Nov-25-25 02:00PM	FDA Greenlights Novartis' Gene Replacement Treatment for SMA (Zacks)
01:08PM	Sarepta's Stock Rises on Positive Updates on DM1 Therapy (Zacks)
Nov-21-25 10:15AM	NVS Ups Sales Projections as Key Drugs and Collaborations Fuel Growth (Zacks)
Nov-20-25 03:45PM	These 15 stocks are still showing momentum - and a market-beating edge (MarketWatch)
09:31AM	US healthcare group Abbott bets on cancer screening technology in $23bn deal (Financial Times)
01:51AM	Loading…
01:51AM	Novartis Expects Steady Sales Growth Through 2030 (The Wall Street Journal)
Nov-10-25 05:25PM	Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
04:05PM	Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights (PR Newswire)
Nov-07-25 04:34PM	Halper Sadeh LLC Encourages WTRG, PLYM, RNA Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
Nov-04-25 10:00AM	Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Nov-03-25 01:34AM	Avidity Biosciences (RNA) Soars 42% on $12-Billion Novartis Merger (Insider Monkey)
Oct-31-25 09:44AM	Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think) (Motley Fool)
Oct-30-25 12:23PM	Halper Sadeh LLC Encourages RNA, JAMF, AWK Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
10:00AM	Analysts Estimate Avidity Biosciences, Inc. (RNA) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-29-25 02:49PM	Fresh List of Stocks With Short Squeeze Potential (Schaeffer's Research)
Oct-28-25 10:14AM	Novartis Lags Q3 Earnings, Announces $12B Avidity Biosciences Acquisition (Zacks)
09:42AM	Warner Bros. Discovery upgraded, F5 downgraded: Wall Street's top analyst calls (The Fly)
09:17AM	Avidity Biosciences (RNA) Moves 42.4% Higher: Will This Strength Last? (Zacks)
06:26AM	Novartis Expects to Ride Out Patent Losses With Sales, Profit Growth Ahead (The Wall Street Journal)
06:11AM	S&P Futures Muted After Record Rally, FOMC Meeting and Earnings in Focus (Barchart)
05:24AM	Loading…
05:24AM	Avidity Biosciences (RNA) Soars to All-Time High on Looming $12-Billion Merger with Novartis (Insider Monkey)
04:00AM	Novartis $12B Avidity deal shows a willingness to take big swings in neuroscience (Pharma Voice)
Oct-27-25 05:12PM	Why Avidity Biosciences Stock Blasted 42% Higher Today (Motley Fool) +42.42%
05:09PM	Health Care Roundup: Market Talk (The Wall Street Journal)
04:54PM	This biotech's stock soared as investors look for the next buyout target (MarketWatch)
04:51PM	Stocks to Watch Monday: Amazon, Nvidia, Novartis, Keurig Dr Pepper (The Wall Street Journal)
04:34PM	These Stocks Are Moving the Most Today: Qualcomm, MP Materials, USA Rare Earth, Tesla, Avidity, Newmont, Microsoft, and More (Barrons.com)
01:01PM	HALPER SADEH LLC ENCOURAGES ADVM, PLYM, RNA SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS (PR Newswire)
12:55PM	Novartis Just Dropped $12 Billion on a Biotech Moonshot--Here's What Investors Need to Know (GuruFocus.com)
12:07PM	Why Avidity Biosciences And Dyne Therapeutics Stocks Soared 40% Monday (Investopedia)
11:16AM	Novartis Avidity Deal Is a Green Light for Biotech Rally (Barrons.com)
09:38AM	Stocks to Watch Monday: Nvidia, Novartis, Keurig Dr Pepper (The Wall Street Journal)
09:24AM	Novartis to buy Avidity for $12B, Keurig Dr Pepper raises outlook (Yahoo Finance Video)
08:25AM	5 Things to Know Before the Stock Market Opens (Investopedia)
08:19AM	USA Rare Earth, Iren, Novartis, Softbank: Trending Stocks (Yahoo Finance Video)
06:49AM	Fed, Tech Earnings and Trump-Xi Talks. Why One Matters Most for Markets. (Barrons.com)
06:08AM	MP Materials slumps, Avidity Biosciences surges and other movers (MarketWatch)
05:51AM	Novartis agrees to buy Avidity Biosciences for $12bn (Pharmaceutical Technology)
05:26AM	Dyne, Avidity stocks soar as Novartis strikes $12 bln biotech deal (Investing.com)
04:59AM	Stock Market Today: Dow set for 200-point rise, S&P 500 and Nasdaq to pop after weekend talks between U.S. and China (MarketWatch)
04:39AM	Jefferies sees Dyne as key beneficiary of Novartis Avidity buyout (Investing.com)
04:39AM	Novartis Deal Values Avidity Biosciences At $12 Billion (Barrons.com)
Oct-26-25 05:33PM	Novartis Agrees to Acquire Avidity Biosciences for $12 Billion (The Wall Street Journal)
04:25PM	Novartis acquiring US firm Avidity Biosciences for $12 bn (AFP)
03:43PM	Swiss drugmaker Novartis to buy Avidity Biosciences for $12 billion (USA TODAY)
03:29PM	Novartis Deal Values Avidity Biosciences At $12 Billion (Barrons.com)
01:07PM	Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG (PR Newswire)
11:07AM	Novartis to acquire Avidity in $12B bet on RNA drugs for neuromuscular disease (BioPharma Dive)
Oct-16-25 09:00AM	Avidity Biosciences to Participate in Upcoming Investor Conference (PR Newswire)
Oct-13-25 09:00AM	Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026 (PR Newswire)
07:31AM	What Makes Avidity Biosciences (RNA) an Investment Choice? (Insider Monkey)
Oct-06-25 09:00AM	Avidity Biosciences to Present Data from EXPLORE44 Clinical Development Program of Del-Zota in DMD44 at 30th Annual Congress of the World Muscle Society (PR Newswire)
Sep-24-25 04:06AM	Avidity Biosciences (RNA) Announces Positive One-Year Data For its, Del-Zota (Insider Monkey)
Sep-17-25 09:33AM	Netflix upgraded, Five Below initiated: Wall Street's top analyst calls (The Fly)
Sep-15-25 04:01PM	Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire) -10.10%
Sep-13-25 12:01PM	Avidity Biosciences (RNA) Gets 9% Boost from Higher PT, Rating (Insider Monkey)
Sep-12-25 06:45AM	Takeda poaches top Lilly exec; Maze soars on early PKU drug data (BioPharma Dive) +9.02%
Sep-10-25 04:01PM	Avidity Biosciences Announces Proposed Public Offering of Common Stock (PR Newswire) -11.55%
07:00AM	Avidity Biosciences' Del-zota Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in EXPLORE44 and EXPLORE44-OLE Phase 1/2 Trial in People Living with DMD44 (PR Newswire)
12:59AM	Cantor Fitzgerald Reiterates a Buy Rating on Avidity Biosciences (RNA) (Insider Monkey)
Aug-27-25 09:00AM	Avidity Biosciences to Participate in Upcoming Investor Conferences (PR Newswire)
Aug-25-25 02:23PM	RNA Stock Moves More Than 30% in a Week: What's Driving This Rally? (Zacks)
Aug-14-25 09:15AM	Clene Inc. (CLNN) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Aug-13-25 08:15AM	Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
Aug-12-25 05:15PM	Fate Therapeutics (FATE) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Aug-07-25 05:10PM	Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights (PR Newswire)
10:19AM	Avidity (RNA) Gets 26% Jump on Potential Takeover (Insider Monkey)
Aug-06-25 05:10PM	Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Beats Revenue Estimates (Zacks) +26.14%
12:47PM	Avidity Biosciences Rockets As Novartis Reportedly Mulls A Takeover Deal (Investor's Business Daily)
12:00PM	Avidity Biosciences stock soars on Novartis takeover approach report (Investing.com)
11:41AM	Novartis weighs deal for biotech Avidity Biosciences, FT reports (Reuters)
Jul-28-25 09:39AM	Facioscapulohumeral Muscular Dystrophy Pipeline Market Insight Report 2025 \| In-depth Analysis of 10+ Companies and 12+ Pipeline Drugs (GlobeNewswire)
09:00AM	Avidity Biosciences Announces Completion of Enrollment for HARBOR, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory Submission (PR Newswire)
Jul-26-25 11:03AM	Avidity (RNA) Jumps 9.2% on Drug Candidate's Breakthrough Therapy Designation (Insider Monkey)
Jul-23-25 09:00AM	Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping (PR Newswire)
Jul-13-25 06:15AM	Raymond James Predicts Up to ~760% Surge for These 2 Strong Buy Stocks (TipRanks)
Jun-11-25 08:03PM	Avidity Biosciences, Inc. (RNA) Initiated with a Strong Buy at Raymond James (Insider Monkey)
09:45AM	Raymond James bullish on biotech firms on favorable valuation (Investing.com)
09:00AM	Avidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD Society International Research Congress (PR Newswire)
Jun-10-25 09:25AM	Avidity Biosciences price target raised to $75 from $65 at Chardan (TipRanks)
Jun-09-25 02:04PM	Avidity Biosciences Touts Encouraging Functional Gains And Biomarker Reductions In Rare Muscular Weakness Disease Trial (Benzinga) -9.88%
07:01AM	Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants (PR Newswire)
07:00AM	Avidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the U.S. is Open for Del-Brax and Initiates the Global, Confirmatory Phase 3 FORWARD Study in FSHD (PR Newswire)
May-21-25 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
May-08-25 05:55PM	Avidity Biosciences, Inc. (RNA) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +9.63%
04:05PM	Avidity Biosciences Reports First Quarter 2025 Financial Results and Recent Highlights (PR Newswire)
May-06-25 09:00AM	Avidity Biosciences to Participate in Upcoming Investor Conference (PR Newswire) -18.65%
Apr-24-25 05:15PM	Gilead Sciences (GILD) Q1 Earnings and Revenues Lag Estimates (Zacks)
Apr-22-25 05:30AM	Trumps FDA Sends a Bullish Signal to Biotech (The Wall Street Journal)

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hughes Steven George	Chief Medical Officer	Jan 21 '26	Sale	72.45	4,895	354,643	31,599	Jan 23 05:34 PM
Boyce Sarah	President and CEO	Jan 21 '26	Sale	72.45	14,387	1,042,338	269,007	Jan 23 05:34 PM
Flanagan W. Michael	Chief Scientific Officer	Jan 21 '26	Sale	72.45	6,534	473,388	85,093	Jan 23 05:33 PM
MacLean Michael F	Chief Financial Officer	Jan 21 '26	Sale	72.45	4,542	329,068	59,290	Jan 23 05:33 PM
LEVIN ARTHUR A	Director	Jan 21 '26	Sale	72.45	1,758	127,367	16,562	Jan 23 05:33 PM
McCarthy Teresa	Chief Human Resources Officer	Jan 21 '26	Sale	72.45	2,929	212,206	113,938	Jan 23 05:33 PM
Boyce Sarah	President and CEO	Jan 07 '26	Sale	72.23	8,576	619,444	283,394	Jan 09 05:13 PM
Calderaro Charles III	Chief Technical Officer	Jan 07 '26	Sale	72.23	3,727	269,201	49,797	Jan 09 05:13 PM
McCarthy Teresa	Chief Human Resources Officer	Jan 07 '26	Sale	72.23	1,965	141,932	116,867	Jan 09 05:13 PM
Moriarty John B	Chief Legal Officer	Jan 07 '26	Sale	72.23	2,374	171,474	74,557	Jan 09 05:12 PM
MacLean Michael F	Chief Financial Officer	Jan 07 '26	Sale	72.23	1,974	142,582	63,832	Jan 09 05:12 PM
Hughes Steven George	Chief Medical Officer	Jan 07 '26	Sale	72.23	2,373	171,402	36,494	Jan 09 05:12 PM
Flanagan W. Michael	Chief Scientific Officer	Jan 07 '26	Sale	72.23	2,373	171,402	91,627	Jan 09 05:12 PM
Hughes Steven George	Chief Medical Officer	Oct 22 '25	Option Exercise	10.16	2,209	22,443	41,076	Oct 24 04:56 PM
Hughes Steven George	Chief Medical Officer	Oct 22 '25	Sale	47.54	2,209	105,015	38,867	Oct 24 04:56 PM
McCarthy Teresa	Chief Human Resources Officer	Oct 15 '25	Option Exercise	22.34	20,000	446,800	117,130	Oct 17 04:27 PM
McCarthy Teresa	Chief Human Resources Officer	Oct 15 '25	Sale	50.15	20,000	1,003,058	97,130	Oct 17 04:27 PM
Mosbrooker Eric	Chief Commercial Officer	Oct 03 '25	Option Exercise	9.05	6,562	59,386	61,562	Oct 07 04:11 PM
Mosbrooker Eric	Chief Commercial Officer	Oct 03 '25	Sale	45.38	6,562	297,771	55,000	Oct 07 04:11 PM
Hughes Steven George	Chief Medical Officer	Sep 22 '25	Option Exercise	10.16	2,208	22,433	41,075	Sep 23 04:57 PM
Hughes Steven George	Chief Medical Officer	Sep 22 '25	Sale	40.58	2,208	89,601	38,867	Sep 23 04:57 PM
McCarthy Teresa	Chief Human Resources Officer	Sep 15 '25	Option Exercise	22.34	15,000	335,100	112,130	Sep 17 04:03 PM
McCarthy Teresa	Chief Human Resources Officer	Sep 15 '25	Sale	41.41	15,000	621,142	97,130	Sep 17 04:03 PM
Hughes Steven George	Chief Medical Officer	Sep 15 '25	Option Exercise	6.57	1,542	10,131	40,409	Sep 17 04:02 PM
Hughes Steven George	Chief Medical Officer	Sep 15 '25	Sale	45.41	1,542	70,022	38,867	Sep 17 04:02 PM
Flanagan W. Michael	Chief Scientific Officer	Sep 11 '25	Option Exercise	14.22	20,000	284,400	100,195	Sep 12 04:07 PM
Flanagan W. Michael	Chief Scientific Officer	Sep 11 '25	Sale	38.94	20,000	778,702	80,195	Sep 12 04:07 PM
WILLIAM MICHAEL FLANAGAN	Officer	Sep 11 '25	Proposed Sale	46.40	20,000	928,000		Sep 11 04:24 PM
WILSON TROY EDWARD	Director	Sep 05 '25	Option Exercise	12.48	14,500	180,960	83,925	Sep 09 05:53 PM
WILSON TROY EDWARD	Director	Sep 05 '25	Sale	50.00	29,500	1,475,000	54,425	Sep 09 05:53 PM
Boyce Sarah	President and CEO	Sep 05 '25	Option Exercise	1.24	50,000	62,000	355,871	Sep 05 06:56 PM
Boyce Sarah	President and CEO	Sep 05 '25	Sale	49.95	50,000	2,497,435	305,871	Sep 05 06:56 PM
Mosbrooker Eric	Chief Commercial Officer	Sep 03 '25	Option Exercise	9.05	6,563	59,395	61,563	Sep 05 06:32 PM
Mosbrooker Eric	Chief Commercial Officer	Sep 03 '25	Sale	47.07	6,563	308,936	55,000	Sep 05 06:32 PM
SARAH BOYCE	Director	Sep 05 '25	Proposed Sale	48.47	50,000	2,423,500		Sep 05 04:25 PM
WILSON TROY EDWARD	Chairman	Sep 05 '25	Proposed Sale	50.00	95,052	4,752,600		Sep 05 04:10 PM
ERIC MOSBROOKER	Officer	Sep 03 '25	Proposed Sale	47.23	19,688	929,864		Sep 03 04:31 PM
Gallagher Kathleen P.	Chief Program Officer	Sep 02 '25	Sale	47.42	188	8,915	50,204	Sep 02 08:30 PM
Boyce Sarah	President and CEO	Aug 28 '25	Option Exercise	1.24	25,000	31,000	330,871	Aug 29 04:28 PM
Boyce Sarah	President and CEO	Aug 28 '25	Sale	49.39	25,000	1,234,700	305,871	Aug 29 04:28 PM
SARAH BOYCE	Director	Aug 28 '25	Proposed Sale	47.82	25,000	1,195,500		Aug 28 04:21 PM
Hughes Steven George	Chief Medical Officer	Aug 22 '25	Option Exercise	10.16	2,208	22,433	41,075	Aug 22 05:20 PM
Hughes Steven George	Chief Medical Officer	Aug 22 '25	Sale	46.40	2,208	102,462	38,867	Aug 22 05:20 PM
McCarthy Teresa	Chief Human Resources Officer	Aug 15 '25	Option Exercise	22.34	10,000	223,400	107,130	Aug 15 05:50 PM
McCarthy Teresa	Chief Human Resources Officer	Aug 15 '25	Sale	46.56	10,000	465,632	97,130	Aug 15 05:50 PM
TERESA MCCARTHY	Officer	Aug 15 '25	Proposed Sale	46.07	45,000	2,073,150		Aug 15 04:27 PM
MacLean Michael F	Chief Financial Officer	Aug 06 '25	Sale	42.73	30,914	1,320,844	65,806	Aug 15 04:09 PM
Hughes Steven George	Chief Medical Officer	Aug 13 '25	Option Exercise	6.57	1,542	10,131	40,409	Aug 15 04:07 PM
Hughes Steven George	Chief Medical Officer	Aug 13 '25	Sale	46.66	1,542	71,950	38,867	Aug 15 04:07 PM
STEVEN GEORGE HUGHES	Officer	Aug 13 '25	Proposed Sale	46.23	9,709	448,847		Aug 13 04:31 PM
Mosbrooker Eric	Chief Commercial Officer	Aug 06 '25	Option Exercise	9.05	124,687	1,128,417	185,807	Aug 08 05:45 PM
Mosbrooker Eric	Chief Commercial Officer	Aug 06 '25	Sale	44.06	130,807	5,763,697	55,000	Aug 08 05:45 PM
WILSON TROY EDWARD	Director	Aug 06 '25	Option Exercise	12.14	29,500	358,260	91,425	Aug 08 05:42 PM
WILSON TROY EDWARD	Director	Aug 06 '25	Sale	45.00	65,554	2,949,930	17,776	Aug 08 05:42 PM
WILSON TROY EDWARD	Director	Aug 06 '25	Sale	45.00	29,500	1,327,500	69,425	Aug 08 05:42 PM
LEVIN ARTHUR A	Director	Aug 06 '25	Option Exercise	22.34	107,500	2,401,550	127,150	Aug 08 05:41 PM
LEVIN ARTHUR A	Director	Aug 06 '25	Sale	47.62	107,500	5,118,881	19,650	Aug 08 05:41 PM
Hughes Steven George	Chief Medical Officer	Aug 06 '25	Option Exercise	12.21	47,451	579,180	90,517	Aug 08 05:39 PM
Hughes Steven George	Chief Medical Officer	Aug 06 '25	Sale	42.74	81,434	3,480,269	38,867	Aug 08 05:39 PM
ERIC MOSBROOKER	Officer	Aug 06 '25	Proposed Sale	38.26	130,807	5,004,676		Aug 06 04:23 PM
STEVEN GEORGE HUGHES	Officer	Aug 06 '25	Proposed Sale	38.26	81,434	3,115,665		Aug 06 04:23 PM
ARTHUR LEVIN	Director	Aug 06 '25	Proposed Sale	38.26	107,500	4,112,950		Aug 06 04:23 PM
MICHAEL MACLEAN	Officer	Aug 06 '25	Proposed Sale	38.26	30,914	1,182,770		Aug 06 04:22 PM
WILSON TROY EDWARD	Chairman	Aug 06 '25	Proposed Sale	45.00	95,054	4,277,430		Aug 06 04:08 PM
Moriarty John B	Chief Legal Officer	Aug 04 '25	Sale	36.21	2,245	81,291	47,755	Aug 05 05:27 PM
Gallagher Kathleen P.	Chief Program Officer	Jun 17 '25	Sale	30.24	911	27,549	50,392	Jun 18 06:02 PM
KATHLEEN GALLAGHER	Officer	Jun 17 '25	Proposed Sale	29.80	911	27,148		Jun 17 04:19 PM
Flanagan W. Michael	Chief Scientific Officer	Jun 11 '25	Option Exercise	14.22	20,000	284,400	100,195	Jun 12 06:18 PM
Flanagan W. Michael	Chief Scientific Officer	Jun 11 '25	Sale	32.88	20,000	657,694	80,195	Jun 12 06:18 PM
WILLIAM MICHAEL FLANAGAN	Officer	Jun 11 '25	Proposed Sale	33.62	20,000	672,400		Jun 11 04:31 PM
Gallagher Kathleen P.	Chief Program Officer	Jun 02 '25	Option Exercise	16.65	5,875	97,819	56,429	Jun 04 04:48 PM
Gallagher Kathleen P.	Chief Program Officer	Jun 02 '25	Sale	32.48	5,875	190,833	50,554	Jun 04 04:48 PM
KATHLEEN GALLAGHER	Officer	Jun 02 '25	Proposed Sale	30.98	5,875	182,008		Jun 02 04:37 PM
Gallagher Kathleen P.	Chief Program Officer	May 01 '25	Option Exercise	16.65	5,875	97,819	56,429	May 02 07:55 PM
Gallagher Kathleen P.	Chief Program Officer	May 01 '25	Sale	32.40	5,875	190,324	50,554	May 02 07:55 PM
KATHLEEN GALLAGHER	Officer	May 01 '25	Proposed Sale	32.65	5,875	191,819		May 01 04:57 PM
Gallagher Kathleen P.	Chief Program Officer	Apr 01 '25	Option Exercise	14.81	5,875	87,004	56,100	Apr 03 04:56 PM
Gallagher Kathleen P.	Chief Program Officer	Apr 01 '25	Sale	27.83	5,875	163,486	50,554	Apr 03 04:56 PM
Hughes Steven George	Chief Medical Officer	Mar 20 '25	Sale	31.06	9,578	297,491	72,850	Mar 21 06:44 PM
Boyce Sarah	President and CEO	Mar 20 '25	Sale	31.06	31,540	979,563	305,871	Mar 21 06:42 PM
Flanagan W. Michael	Chief Scientific Officer	Mar 20 '25	Sale	31.06	11,780	365,868	80,195	Mar 21 06:40 PM
MacLean Michael F	Chief Financial Officer	Mar 20 '25	Sale	31.06	7,935	246,425	96,720	Mar 21 06:38 PM
McCarthy Teresa	Chief Human Resources Officer	Mar 20 '25	Sale	31.06	7,778	241,583	97,130	Mar 21 06:36 PM
Flanagan W. Michael	Chief Scientific Officer	Mar 11 '25	Option Exercise	14.22	20,000	284,400	111,975	Mar 12 04:23 PM
Flanagan W. Michael	Chief Scientific Officer	Mar 11 '25	Sale	30.13	20,000	602,614	91,975	Mar 12 04:23 PM
WILLIAM MICHAEL FLANAGAN	Officer	Mar 11 '25	Proposed Sale	30.04	20,000	600,800		Mar 11 04:35 PM
Gallagher Kathleen P.	Chief Program Officer	Mar 03 '25	Option Exercise	14.70	5,875	86,362	56,429	Mar 04 06:17 PM
Gallagher Kathleen P.	Chief Program Officer	Mar 03 '25	Sale	29.41	5,875	172,807	50,554	Mar 04 06:17 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RNA

Atrium Therapeutics Inc

Upgrade your FINVIZ experience